Abstract: A floor covering includes a plastics core, which has an upper side and a lower side, a functional layer and a reinforcement mat arranged on the upper side, and which has fibers and voids located therebetween, wherein the reinforcement mat is located between the upper side of the plastics core and the functional layer, the reinforcement mat and the functional layer constituting a preproduced unit, in which the reinforcement mat is fastened to the functional layer, wherein the plastics core is joined with the preproduced unit in such a way that the plastics core is joined with the fibers of the reinforcement mat and through the voids of the reinforcement mat with the functional layer such that the floor covering has a high degree of dimensional stability, and a method for producing the floor covering.

Abstract: A floor covering includes a plastics core, which has an upper side and a lower side, a functional layer and a reinforcement mat arranged on the upper side, and which has fibers and voids located therebetween, wherein the reinforcement mat is located between the upper side of the plastics core and the functional layer, the reinforcement mat and the functional layer constituting a preproduced unit, in which the reinforcement mat is fastened to the functional layer, wherein the plastics core is joined with the preproduced unit in such a way that the plastics core is joined with the fibers of the reinforcement mat and through the voids of the reinforcement mat with the functional layer such that the floor covering has a high degree of dimensional stability, and a method for producing the floor covering.

Abstract: An underlay mat (10) for floor coverings, includes a polyurethane layer (14), a self-adhesive film (20) on the topside of the polyurethane layer (14) and which includes a carrier film (12), a layer of adhesive (22) applied to carrier film (12), and a mesh structure (24) made of fibers which is embedded in the adhesive layer (22), and a removable protective film (26) on the topside of self-adhesive film (20).

Abstract: A method for producing a laminate (1), preferably for a floor covering, wherein the laminate (1) has a decorative layer and a wear layer made of polyurethane, includes the following steps: applying a first liquid polyurethane material (12) on a release layer (11) to form the wear layer, inserting a decorative sheet (14) into the first polyurethane material (12), applying a second liquid polyurethane material (17) on the decorative sheet (14), which is impregnated with the first polyurethane material (12) and with the second polyurethane material (17), supplying heat energy for curing the first polyurethane material (12) and the second polyurethane material (17), and separating the release layer (11) from the wear layer, wherein the heat energy is supplied to the first polyurethane material (12) and the second polyurethane material (17) from below through the release layer.

Abstract: An underlay mat (10) for floor coverings, includes a polyurethane layer (14), a self-adhesive film (20) on the topside of the polyurethane layer (14) and which includes a carrier film (12), a layer of adhesive (22) applied to carrier film (12), and a mesh structure (24) made of fibers which is embedded in the adhesive layer (22), and a removable protective film (26) on the topside of self-adhesive film (20).

Abstract: An underlay mat (10) for floor coverings, includes a polyurethane layer (14), a nonwoven backing (18) on the underside of polyurethane layer (14), a self-adhesive film (20) on the topside of the polyurethane layer (14) and which includes a carrier film (12), a layer of adhesive (22) applied to carrier film (12), and a mesh structure (24) made of fibers which is embedded in the adhesive layer (22), and a removable protective film (26) on the topside of self-adhesive film (20).

Abstract: A method for producing a laminate (1), preferably for a floor covering, wherein the laminate (1) has a decorative layer and a wear layer made of polyurethane, includes the following steps: applying a first liquid polyurethane material (12) on a release layer (11) to form the wear layer, inserting a decorative sheet (14) into the first polyurethane material (12), applying a second liquid polyurethane material (17) on the decorative sheet (14), which is impregnated with the first polyurethane material (12) and with the second polyurethane material (17), supplying heat energy for curing the first polyurethane material (12) and the second polyurethane material (17), and separating the release layer (11) from the wear layer, wherein the heat energy is supplied to the first polyurethane material (12) and the second polyurethane material (17) from below through the release layer.

Abstract: An elastic floor covering (10) in the form of sheets, which can be rolled up, includes a soft core (18) of polyurethane and a layered compound structure (24) disposed on the core (18), and the back of the floor covering (10) is formed by a fiber mat, the fibers of which consist of glass, PET, PP, polyester or renewable raw materials, and which is sealed by a barrier layer on its side facing the core.

Abstract: A floor panel (10, 100) with an average density of between 1.5 and 2.5 g/cm3 and a mass per unit area (EN ISO 23997) of between 3.5 and 8 kg/m2, includes at least one soft elastic core layer (12) made from a PU material and a non-slip backing (22) having an embossing, with the lateral edges of the floor panel (10, 100) being contrived such that two adjacently installed floor panels (10, 100) abut against each other along their lateral edges in a non-locking manner.

Abstract: The present invention relates generally to a method of increasing lipid oxidation in a mammal and to agents useful for same. More particularly, the present invention relates to a method of increasing lipid oxidation in a mammal by administering a ligand which interacts with the IL-6 receptor and signals via interaction with a gp130/LIF receptor heterodimer. In a related aspect, the present invention provides a method of increasing insulin sensitivity in a mammal. The method of present invention is useful, inter alia, in the treatment and/or prophylaxis of conditions characterized by unwanted lipid accumulation (such as obesity, obesity induced-metabolic disorders, type II diabetes, dyslipidemia, glucose intolerance, insulin resistance, obstructive sleep apnea, cardiovascular disease or non-alcoholic fatty liver disease) or inadequate insulin sensitivity.

Abstract: A floor panel (10, 100) with an average density of between 1.5 and 2.5 g/cm3 and a mass per unit area (EN ISO 23997) of between 3.5 and 8 kg/m2, includes at least one soft elastic core layer (12) made from a PU material and a non-slip backing (22) having an embossing, with the lateral edges of the floor panel (10, 100) being contrived such that two adjacently installed floor panels (10, 100) abut against each other along their lateral edges in a non-locking manner.

Abstract: An underlay mat (10) for floor coverings, includes a polyurethane layer (14), a nonwoven backing (18) on the underside of polyurethane layer (14), a self-adhesive film (20) on the topside of the polyurethane layer (14) and which includes a carrier film (12), a layer of adhesive (22) applied to carrier film (12), and a mesh structure (24) made of fibers which is embedded in the adhesive layer (22), and a removable protective film (26) on the topside of self-adhesive film (20).

Abstract: An elastic floor panel (10), includes a dimensionally stable core (18) of polyurethane and a layered compound structure (24), which is disposed on the core (18), and the back of the floor panel (10) is coated with a fiber mat (20), the fibers of which consist of glass, PET, PP, polyester or renewable raw materials, and which is sealed on the side facing the core by a barrier layer.

Abstract: An elastic floor covering (10) in the form of sheets, which can be rolled up, includes a soft core (18) of polyurethane and a layered compound structure (24) disposed on the core (18), and the back of the floor covering (10) is formed by a fiber mat, the fibers of which consist of glass, PET, PP, polyester or renewable raw materials, and which is sealed by a barrier layer on its side facing the core.

Abstract: Nucleic acid molecule selected from the group consisting of (a) a nucleic acid molecule having a nucleotide sequence shown in SEQ ID: NO 1, (b) a nucleic acid molecule which encodes a peptide having an amino acid sequence shown in SEQ ID: NO 2, (c) a nucleic acid molecule whose complementary strand hybridizes to a nucleic acid molecule according to (a) or (b) and which codes for a peptide which binds to ciliary neurotrophic factor receptor (CNTFR), the peptide binding with lower affinity than ciliary neurotrophic factor to the interleukin-6 receptor (IL-6R), (d) a nucleic acid molecule whose nucleotide sequence differs from the nucleotide sequence of a nucleic acid molecule according to (c) due to the degenerated genetic code, the codon at positions 82-84 of the nucleic acid molecule according to (a) coding for a non-positively charged amino acid, and the peptide at position 28 shown in SEQ ID: NO 2 having a non-positively charged amino acid residue.

Abstract: Nucleic acid molecule selected from the group consisting of (a) a nucleic acid molecule having a nucleotide sequence shown in SEQ ID: NO 1, (b) a nucleic acid molecule which encodes a peptide having an amino acid sequence shown in SEQ ID: NO 2, (c) a nucleic acid molecule whose complementary strand hybridizes to a nucleic acid molecule according to (a) or (b) and which codes for a peptide which binds to ciliary neurotrophic factor receptor (CNTFR), the peptide binding with lower affinity than ciliary neurotrophic factor to the interleukin-6 receptor (IL-6R), (d) a nucleic acid molecule whose nucleotide sequence differs from the nucleotide sequence of a nucleic acid molecule according to (c) due to the degenerated genetic code, the codon at positions 82-84 of the nucleic acid molecule according to (a) coding for a non-positively charged amino acid, and the peptide at position 28 shown in SEQ ID: NO 2 having a non-positively charged amino acid residue.

Abstract: The present invention relates generally to a method of increasing lipid oxidation in a mammal and to agents useful for same. More particularly, the present invention relates to a method of increasing lipid oxidation in a mammal by administering a ligand which interacts with the IL-6 receptor and signals via interaction with a gp130/LIF receptor heterodimer. In a related aspect, the present invention provides a method of increasing insulin sensitivity in a mammal. The method of present invention is useful, inter alia, in the treatment and/or prophylaxis of conditions characterised by unwanted lipid accumulation (such as obesity, obesity induced-metabolic disorders, type II diabetes, dyslipidemia, glucose intolerance, insulin resistance, obstructive sleep apnea, cardiovascular disease or non-alcoholic fatty liver disease) or inadequate insulin sensitivity.

Abstract: Described are soluble gp130 polypeptide monomers and dimers, wherein, in a preferred embodiment, at least one of the three amino acid residues Thr102 GIn113 or ASn114 of the N-terminal Ig-like domain of gp130 is mutated to Tyr102, Phe113 or Leu114, respectively. These mutations, alone or in combination, specifically enhance binding of gp130 to its ligand complex of interleukin-6 and soluble interleukin-6 receptor, thus increasing the biological activity of the gp130 muteins. In a particularly preferred embodiment, all three mutations are combined in the triple mutein Thr102Tyr/Gln113Phe/Asn114Leu (T102Y/Q113F/N114L). Moreover, a pharmaceutical composition containing said monomers or dimers and various medical uses are described.

Abstract: Described are soluble gp130 polypeptide monomers and dimers, wherein, in a preferred embodiment, at least one of the three amino acid residues Thr102 Gln113 or Asn114 of the N-terminal Ig-like domain of gp130 is mutated to Tyr102, Phe113 or Leu114, respectively. These mutations, alone or in combination, specifically enhance binding of gp130 to its ligand complex of interleukin-6 and soluble interleukin-6 receptor, thus increasing the biological activity of the gp130 muteins. In a particularly preferred embodiment, all three mutations are combined in the triple mutein Thr102Tyr/Gln113Phe/Asn114Leu (T102Y/Q113F/N114L). Moreover, a pharmaceutical composition containing said monomers or dimers and various medical uses are described.

Abstract: The present invention relates to methods for preventing or treating toxicities associated with exposure to ionizing radiation or to chemotherapy. Particularly, the present invention relates to methods for preventing or treating toxicities associated with radiation or chemotherapy comprising administering to a subject in need of such treatment polypeptide complexes comprising an IL-6 linked to a soluble IL-6 receptor, the polypeptide complexes capable of preventing or treating toxicities, particularly xerostomia.